

Declarations of Interest

S34 EFFECT OF 8 AND 12 WEEKS' ONCE-DAILY TIOTROPIUM AND OLODATEROL, ALONE AND COMBINED WITH EXERCISE TRAINING, ON EXERCISE ENDURANCE DURING WALKING IN PATIENTS WITH COPD

10.1136/thoraxjnl-2016-209333.464

T Troosters has received grants from Innovative Medicines Initiative Joint Undertaking and speaker fees from Boehringer Ingelheim and GlaxoSmithKline.

J Bourbeau has received grants from the Canadian Institute of Health Research R&D collaborative programme (AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck, Nycomed, Novartis), Canadian Respiratory Research Network, Respiratory Health Network of the FRQS and Research Institute of the MUHC, and an educational grant from GlaxoSmithKline.

F Maltais has received grants from Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, Nycomed and Pfizer, personal fees from Boehringer Ingelheim, GlaxoSmithKline and Novartis, and other financial support from GlaxoSmithKline.

N Leidy is employed by Evidera, a health-care research firm that provides consulting and other research services to pharmaceutical and other organisations including the study sponsor.

D Erzen, D De Sousa, L Korducki and A Hamilton are employees of Boehringer Ingelheim Pharma GmbH & Co. KG.

KL Lavoie reports personal fees from Boehringer Ingelheim for personnel training as well as a grant from AbbVie and personal fees from Bayer, Janssen, Novartis, AbbVie, Mundipharma and Almirall.

W Janssens has no conflict of interest to report.

S109 TARGETING THE PROSTACYCLIN PATHWAY IN THE TREATMENT OF CONNECTIVE TISSUE DISEASE ASSOCIATED PULMONARY ARTERIAL HYPERTENSION (PAH): INSIGHTS FROM THE RANDOMISED CONTROLLED GRIPHON TRIAL WITH SELEXIPAG

10.1136/thoraxjnl-2016-209333.465

The GRIPHON study was sponsored by Actelion Pharmaceuticals Ltd.

G Coghlan: Consulting fees: Actelion Pharmaceuticals Ltd, Bayer HealthCare, GlaxoSmithKline, GenenTech, United Therapeutics. Speaker's honoraria and research grants: Actelion Pharmaceuticals Ltd, GlaxoSmithKline, Bayer HealthCare, United Therapeutics.

S Gain: Consulting fees/honoraria: Actelion Pharmaceuticals Ltd, Bayer HealthCare, GlaxoSmithKline, United Therapeutics, Novartis, Pfizer. Steering Committee membership: Actelion Pharmaceuticals Ltd, GlaxoSmithKline, United Therapeutics, Novartis.

R Channick: Consulting fees/honoraria: Actelion Pharmaceuticals Ltd, Bayer HealthCare, United Therapeutics. Steering Com-

mittee membership: Actelion Pharmaceuticals Ltd. L Di Scala: Employee Actelion Pharmaceuticals Ltd.

N Galié: Consulting fees/honoraria: Actelion Pharmaceuticals Ltd, Bayer HealthCare, GlaxoSmithKline, Pfizer. Steering Committee membership: Actelion Pharmaceuticals Ltd.

HA Ghofrani: Consulting fees/honoraria: Actelion Pharmaceuticals Ltd, Bayer HealthCare, Gilead Sciences Inc, GlaxoSmithKline, Merck & Co, Novartis Corporation, Pfizer Inc. Steering Committee membership: Actelion Pharmaceuticals Ltd, Bayer HealthCare, Gilead Sciences Inc, GlaxoSmithKline, Merck & Co, Novartis Corporation, Pfizer Inc.

MM Hoepfer: Consulting fees/honoraria: Actelion Pharmaceuticals Ltd, Bayer HealthCare, GlaxoSmithKline, Pfizer, Gilead Sciences. Steering Committee membership: Actelion Pharmaceuticals Ltd.

I Lang: Consulting fees/honoraria: Actelion Pharmaceuticals Ltd, Bayer HealthCare, GlaxoSmithKline, Novartis Corporation, United Therapeutics. Steering Committee membership: Actelion Pharmaceuticals Ltd.

V McLaughlin: Consulting fees/honoraria: Actelion Pharmaceuticals Ltd, Bayer HealthCare, Gilead Sciences Inc, United Therapeutics, Ikaria, Novartis. Steering Committee membership: Actelion Pharmaceuticals Ltd, Bayer HealthCare, Gilead Sciences Inc, United Therapeutics, Ikaria.

R Preiss: Employee Actelion Pharmaceuticals Ltd. LJ Rubin: Consulting fees/honoraria: Actelion Pharmaceuticals Ltd, Arena Pharmaceuticals, GeNO Pharmaceuticals, Lung Biotechnology, Gilead Sciences Inc, United Therapeutics. Steering Committee membership: Actelion Pharmaceuticals Ltd.

G Simonneau: Consulting fees/honoraria: Actelion Pharmaceuticals Ltd, Bayer HealthCare, Eli Lilly & Co, GlaxoSmithKline, Novartis Corporation, Pfizer Inc. Steering Committee membership: Actelion Pharmaceuticals Ltd. O Sitbon: Consulting fees/honoraria: Actelion Pharmaceuticals Ltd, Bayer HealthCare, GlaxoSmithKline, Pfizer Inc, United Therapeutics. Steering Committee membership: Actelion Pharmaceuticals Ltd.

S112 LONG-TERM SAFETY AND EFFICACY OF IVACAFTOR IN PEDIATRIC PATIENTS AGED 2-5 YEARS WITH CYSTIC FIBROSIS AND A CFTR GATING MUTATION

10.1136/thoraxjnl-2016-209333.466

JC Davies has served on advisory boards, undertaken educational activities, and served as national/site principal investigator for trials, for which her institution has received funding from Vertex Pharmaceuticals Incorporated.

S Robertson is an employee of Vertex Pharmaceuticals Incorporated and may own stock or stock options in that company.

J Cooke is an employee of Vertex Pharmaceuticals Incorporated and may own stock or stock options in that company.

M Higgins is an employee of Vertex Pharmaceuticals Incorporated and my own stock or stock options in that company.

M Rosenfeld: has served as a national and site investigator for trials and as a consultant, for which her institution received funding from Vertex Pharmaceuticals Incorporated.